Navigation Links
Biomerix Corporation Receives ISO 13485 Certification
Date:6/15/2009

Company with Innovative Biomaterial Technology Achieves Significant Milestone in CE Mark Approval Pathway

FREMONT, Calif., June 15 /PRNewswire/ -- Biomerix Corporation, a medical technologies company developing products using its novel Biomerix Biomaterial(TM), a three-dimensional scaffold for biointegrative tissue repair, announced today that it has received an ISO 13485 Certificate of Registration. Issued by the British Standards Institution (BSI), the certification indicates that Biomerix has successfully implemented a quality system that conforms to the exacting International Organization for Standardization (ISO) standards for medical devices. ISO is one of the key regulatory requirements for a CE Mark in the European Union as well as other international markets. The certification applies to the Fremont, CA location which designs, manufactures and distributes finished medical devices and the Somerset, NJ location which manufactures the Biomerix Biomaterial.

ISO 13485 is an internationally recognized standardization system which defines standards for the design, development, production and distribution of medical devices. It ensures conformity with specified quality controls in the development of safe and effective devices. Achievement of ISO 13485:2003 demonstrates Biomerix Corporation's dedication to continuously improve product quality by providing finished medical devices and polymer components that consistently meet customer and regulatory requirements.

"This certification represents a major milestone for Biomerix Corporation and demonstrates our unwavering commitment to producing high-quality devices for our customers. Meeting the ISO standards speaks to our belief in our quality management system and is an important step towards commercialization abroad," commented Kenneth G. Hayes, President and Chief Executive Officer of Biomerix Corporation.

About Biomerix Corporation

Biomerix Corporation develops and manufactures a broad portfolio of implantable medical devices based on its proprietary Biomerix Biomaterial(TM) platform technology. Constructed as an ideal biointegrative scaffold, the Biomerix Biomaterial supports tissue repair and regeneration, leading to better clinical outcomes. Biomerix strives to improve patient outcomes through the development of medical devices for soft tissue repair, neurovascular embolization, spine annular repair, cardiovascular repair and women's health indications, utilizing its innovative Biomaterial.

For more information call 888.308.3620 or visit www.biomerix.com


'/>"/>
SOURCE Biomerix Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Providence Service Corporation Announces Preliminary Results of Annual Meeting of Stockholders
2. Ted Karkus and Karkus Slate of Directors Prevail in Federal Court, Seated as Directors of The Quigley Corporation; Ted Karkus Elected Chairman of the Board
3. Hospital Corporation of America Named to Computerworlds Annual List of Best Places to Work in Information Technology
4. Genaera Corporation Board of Directors Dissolves Corporation and Forms Liquidating Trust
5. Zix Corporation Announces Review of Strategic Alternatives for e-Prescribing Business
6. Response Biomedical Corporation Announces Appointment of Vice President Finance & Administration and Chief Financial Officer
7. Sabinsa Corporation Validates Safety of Garcinia Cambogia Extract in Light of Hydroxycut Warning
8. RiskMetrics Recommends That Providence Service Corporation Stockholders Vote for Providences Director Nominees on the White Proxy Card
9. Somanetics Corporation to Release Second Quarter 2009 Financial Results and Host Conference Call June 17, 2009
10. Genaera Corporation Announces Results of Special Meeting of Stockholders
11. Angelica Corporation Raises Bar Again for Increased Patient Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and ... their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took ... the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive ...
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 26, 2016 One of Australia,s ... formation of a new biotechnology company, Noxopharm Limited [ABN 50 608 ... IPO and to list on the ASX. Noxopharm is ... to enter a Phase 1 clinical study later this year. ... one of the biggest problems facing cancer patients - the ability ...
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... p.m. (Eastern Daylight Time). As previously announced ... into a definitive merger agreement under which Jazz Pharmaceuticals ...
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
Breaking Medicine Technology: